Novel antimicrobial targets from combined pathogen and host genetics.
Johnson
C D
CD
Axys Pharmaceuticals, South San Francisco, CA 90480, USA. carl.johnson@axyspharm.com
Liu
L X
LX
D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D001419:Bacteria / Q000235:genetics; D017173:Caenorhabditis elegans / Q000235:genetics / Q000382:microbiology; D029742:Caenorhabditis elegans Proteins; D004268:DNA-Binding Proteins; D015195:Drug Design; D005786:Gene Expression Regulation / Q000187:drug effects; D005798:Genes, Bacterial; D017238:Genes, Helminth; D015801:Helminth Proteins / Q000235:genetics; D006801:Humans; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases; D017874:Immediate-Early Proteins / Q000235:genetics; D007113:Immunity, Innate; D008322:Mammals / Q000235:genetics; D011393:Procollagen-Proline Dioxygenase; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000235:genetics; D051381:Rats; D014774:Virulence / Q000235:genetics
D000900:Anti-Bacterial Agents; D029742:Caenorhabditis elegans Proteins; D004268:DNA-Binding Proteins; C403074:Egl-9 protein, C elegans; D015801:Helminth Proteins; D017874:Immediate-Early Proteins; C490190:EGLN1 protein, human; D011393:Procollagen-Proline Dioxygenase; C087100:Egln3 protein, rat; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases